Fig. 1 · Structure

Documents & Downloads

AKTI-1/2 (AKT inhibitor VIII)

Cat. No. A11286 CAS 612847-09-3

AKT inhibitor

AKT inhibitor VIII is a cell-permeable and reversible quinoxaline compound that potently and selectively inhibits Akt1/Akt2 activity (IC50 = 58 nM, 210 nM, and 2.12 μM for Akt1, Akt2, and Akt3, respectively, in in vitro kinase assays).

In Stock

Publications for AKTI-1/2

2 publications citing this product

  1. Bjune K, .et al. , PLoS One, 2019, Jun 19;14(6):e0218537 PMID: 31216345
  2. Hoshiba T, .et al. , Biochim Biophys Acta, 2016, Nov;1863(11):2749-2757 PMID: 27558478

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

AKT inhibitor VIII binds an allosteric pocket at the interface of the PH and kinase domains. A 2.7 Å co-crystal structure with human AKT1(1–443) shows an inactive, closed conformation and a stacking interaction with Trp80. The crystallized construct lacks the C-terminal hydrophobic motif. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
Akt1 58 nM
Akt2 210 nM
Akt3 2119 nM

Cellular Effect

Cell Line Activity Value Description Reference
184B5 GI50 25.76 μM Cytotoxicity against human 184B5 cells at 20 uM chloroquine by SRB assay [PMID: 18691894]
184B5 GI50 50.58 μM Cytotoxicity against human 184B5 cells at 10 uM chloroquine by SRB assay [PMID: 18691894]
184B5 GI50 60.6 μM Cytotoxicity against human 184B5 cells by SRB assay [PMID: 18691894]
Hep 3B2 IC50 3.5 μM Anticancer activity against human Hep3B cells assessed as inhibition of cell proliferation incubated for 4 days by MTS assay [PMID: 33873056]
HL-60 IC50 5.5 μM Antiproliferative activity against human HL60 cells measured after 3 days by MTS assay [PMID: 26945110]
Huh-7 IC50 4 μM Anticancer activity against human Huh-7 cells assessed as inhibition of cell proliferation incubated for 4 days by MTS assay [PMID: 33873056]
Jurkat IC50 3.5 μM Antiproliferative activity against human Jurkat cells measured after 3 days by MTS assay [PMID: 26945110]
K562 IC50 17 μM Antiproliferative activity against human K562 cells measured after 3 days by MTS assay [PMID: 26945110]
MCF7 GI50 0.05 μM Cytotoxicity against human MCF7 cells in presence of 20 uM chloroquine by SRB assay [PMID: 18691894]
MCF7 GI50 0.41 μM Cytotoxicity against human MCF7 cells in presence of 10 uM chloroquine by SRB assay [PMID: 18691894]
MCF7 GI50 0.92 μM Cytotoxicity against human MCF7 cells by SRB assay [PMID: 18691894]
MDA-MB-231 GI50 2.95 μM Cytotoxicity against human MDA-MB-231 cells in presence of 20 uM chloroquine by SRB assay [PMID: 18691894]
MDA-MB-231 GI50 4.55 μM Cytotoxicity against human MDA-MB-231 cells in presence of 10 uM chloroquine by SRB assay [PMID: 18691894]
MDA-MB-231 GI50 5.31 μM Cytotoxicity against human MDA-MB-231 cells by SRB assay [PMID: 18691894]
MDA-MB-468 GI50 0.85 μM Cytotoxicity against human MDA-MB-468 cells in presence of 20 uM chloroquine by SRB assay [PMID: 18691894]
MDA-MB-468 GI50 2.66 μM Cytotoxicity against human MDA-MB-468 cells in presence of 10 uM chloroquine by SRB assay [PMID: 18691894]
MDA-MB-468 GI50 6.3 μM Cytotoxicity against human MDA-MB-468 cells by SRB assay [PMID: 18691894]
PBMC IC50 > 50 μM Cytotoxicity against PHA induced human PBMC after 3 days by MTS assay [PMID: 26945110]
U-937 IC50 8 μM Antiproliferative activity against human U937 cells measured after 3 days by MTS assay [PMID: 26945110]

19 records · Scroll to view more

AKTI-1/2 (AKT inhibitor VIII) Research Summary

This section summarizes 3 in vitro studies of AKTI-1/2 (AKT inhibitor VIII) from 2 published references.

AKTI-1/2 (AKT inhibitor VIII) In Vitro Studies

In HepG2 cells, 7.5 µM AKT inhibitor VIII for 14 h increased LDLR mRNA and LDLR promoter reporter activity relative to vehicle. A separate transcription-block experiment found similar LDLR mRNA decay, with reported half-lives of 2 h 08 min for inhibitor-treated cells and 1 h 56 min for vehicle. Its inhibitor pretreatment conditions are ambiguous in the published cross-reference. These findings support increased transcription rather than substantial mRNA stabilization in this model. [2]

AKT1 co-crystal defines an allosteric binding site

Biochemical assay · Purified human AKT1(1–443), lacking the C-terminal hydrophobic motif; PDB 3O96 [1]

The ligand occupies the PH/kinase-domain interface in an inactive conformation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
AKT1:Inhibitor VIII co-crystal diffractionResolution 2.7 Å[1]
Ligand binding positionStructural observation PH/kinase-domain interface; ring stacking with Trp80[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.25 mM inhibitor with 4.7 mg/mL AKT1(1–443)
Method
Co-crystallization and X-ray structure determination
Reported limits
A crystallization concentration, not an IC50 or cellular treatment dose. Solvent composition for inhibitor stock is not specified in the crystallization section.
Methods and source locations

Compound reported in the paper: AKT inhibitor VIII (AKTI-1/2); Compound label in the paper: Inhibitor VIII

Evidence for the named research compound in the reported material and model; no Adooq lot validation or salt conversion.

Results; Figures 1, 3, 5B and Table 1; Materials and Methods: Crystallization and structural refinement

AKT1:Inhibitor VIII co-crystal diffraction: X-ray crystallography; one crystal dataset — Results; Table 1; X-ray data collection and refinement

Ligand binding position: Co-crystal structure — Results; Figures 3 and 5B

LDLR mRNA expression and promoter activity in HepG2 cells

Cell-based study · Human HepG2 cells; endogenous LDLR mRNA and LDLR-promoter luciferase reporter [2]

At 7.5 µM for 14 h, AKT inhibitor VIII increased LDLR mRNA and LDLR promoter reporter activity relative to vehicle.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
LDLR mRNA normalized to GAPDHRelative expression Increased; **p < 0.01 versus vehicle; n = 4[2]
LDLR promoter-driven firefly luciferase normalized to RenillaReporter activity Increased; ***p < 0.001 versus vehicle; four independent experiments[2]

Literature-Reported Treatment Conditions

Treatment concentration
7.5 µM
Exposure duration
14 h
Method
Addition to HepG2 cultures; reporter treatment started 24 h after transfection
Vehicle
0.1% (v/v) DMSO; matched DMSO-only control
Co-treatment
None; other AKT inhibitors were separate comparator treatments.
Reported limits
Exact fold changes are not extracted from plotted bars.
Methods and source locations

Compound reported in the paper: AKT inhibitor VIII (AKTI-1/2); Compound label in the paper: AKT inhibitor VIII

Evidence for the named research compound in the reported material and model; no Adooq lot validation or salt conversion.

Figure 2A–B and caption; Reagents and antibodies; Cell cultures; qPCR; reporter assay methods

LDLR mRNA normalized to GAPDH: qPCR; technical duplicates; 2^−ΔΔCt; Fig 2 caption reports 95% confidence intervals — Figure 2A and caption; Quantitative real-time PCR

LDLR promoter-driven firefly luciferase normalized to Renilla: Dual-luciferase reporter assay; Fig 2 caption reports 95% confidence intervals — Figure 2B and caption; Plasmids, transfection and reporter assay

LDLR mRNA decay after transcription blockade

Cell-based study · Human HepG2 cells, vehicle or AKT inhibitor VIII pretreatment followed by actinomycin D [2]

LDLR mRNA decayed similarly to vehicle; reported half-life estimates were close.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
LDLR mRNA half-life after transcription inhibitionEstimated half-life Akt inh VIII: 2 h, 08 min; vehicle: 1 h, 56 min[2]

Literature-Reported Treatment Conditions

Exposure duration
Samples at 0, 2, 4 and 6 h after actinomycin D
Method
qPCR after transcription blockade; each condition normalized to its pre-ActD value
Vehicle
Matched vehicle; shared cell methods specify 0.1% (v/v) DMSO
Co-treatment
Actinomycin D, 5 µg/ml, used to block transcription; not a therapeutic combination.
Reported limits
Inhibitor concentration and pretreatment duration are not unambiguously recoverable: Fig 3 caption refers to nonexistent Fig 1A. Do not import the 7.5 µM/14 h conditions from Fig 2.
Methods and source locations

Compound reported in the paper: AKT inhibitor VIII (AKTI-1/2); Compound label in the paper: AKT inhibitor VIII

Evidence for the named research compound in the reported material and model; no Adooq lot validation or salt conversion.

Figure 3G–H and caption; Statistical analyses; Cell cultures

LDLR mRNA half-life after transcription inhibition: Least-squares regression of qPCR decay data; GAPDH-normalized; five independent experiments in decay panels — Figure 3G–H; Statistical analyses

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 612847-09-3
Applications AKT inhibitor
Formula C34H29N7O
Molecular Weight 551.6
Synonyms AKT inhibitor VIII
SMILES
C1CN(CCC1N2C3=CC=CC=C3NC2=O)CC4=CC=C(C=C4)C5=NC6=CC7=C(C=C6N=C5C8=CC=CC=C8)N=CN7

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 19 mg/mL (34.44 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

AKTI-1/2 (AKT inhibitor VIII) Research References

  1. [1] Wen-I Wu, Walter C. Voegtli, Hillary L. Sturgis, et al. Crystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase Inhibition PLOS ONE (2010). PMID: 20886116 DOI: 10.1371/journal.pone.0012913 Source material
  2. [2] Katrine Bjune, Lene Wierød, Soheil Naderi. Inhibitors of AKT kinase increase LDL receptor mRNA expression by two different mechanisms PLOS ONE (2019). PMID: 31216345 DOI: 10.1371/journal.pone.0218537 Source material

Publications

2 publications citing this product

  1. Bjune K, .et al. , PLoS One, 2019, Jun 19;14(6):e0218537 PMID: 31216345
  2. Hoshiba T, .et al. , Biochim Biophys Acta, 2016, Nov;1863(11):2749-2757 PMID: 27558478

Added to your cart

View Cart Checkout
Loading...